Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03177044
Other study ID # HREC/17/SVHM/92
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date June 1, 2017
Est. completion date December 31, 2021

Study information

Verified date April 2023
Source St Vincent's Hospital Melbourne
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The primary aim of the project is to investigate whether a behavioural training programme improves troublesome bowel symptoms, that people with inflammatory bowel disease continue to have, despite their disease being controlled by medication. The other aim is to determine if there are factors which influence how well the training programme works. People attending an Inflammatory Bowel Disease clinic in a tertiary hospital, with bothersome bowel symptoms despite disease control, will be asked to join the study. This involves 2 to 6 sessions with a pelvic floor trained physiotherapist over a period of 6 months with further follow up at 12 months..


Description:

Inflammatory bowel diseases, chiefly Crohn's disease and ulcerative colitis, are chronic gastrointestinal (gut) conditions which tend to flare up some times and be quiet for other periods of time. They are usually controlled by medication. Inflammatory bowel disease is becoming more common, is usually diagnosed at a young age and is lifelong. A significant number of people with inflammatory bowel disease can have bowel symptoms which are bothersome even when the disease is quiescent. These symptoms include bowel urgency, frequent toileting, incontinence (leakage), constipation (infrequent bowel actions and/or difficulty emptying the bowel), abdominal pain, rectal pain or abdominal bloating. The symptoms can be very embarrassing or stressful, limiting activities and making life less enjoyable. People with these bowel symptoms, but without inflammatory bowel disease, respond to a type of therapy called behavioural treatment. We don't know yet if this treatment helps people with inflammatory bowel disease. Behavioural treatment involves learning about how the bowel works, better ways to manage bowel problems and specific exercises to improve bowel control. Specially trained pelvic floor physiotherapists provide 2-6 sessions, over 6 months, of behavioural treatment which may include the use of biofeedback techniques. Participants will be asked to complete surveys at the beginning and end of treatment and 12 months later. There are no recognised risks or unwanted side effects caused by behavioural treatment. The benefits are that people with inflammatory bowel disease will have an alternative low cost, low risk treatment which enables them to self-manage bowel symptoms and improve the quality of their life long term.


Recruitment information / eligibility

Status Completed
Enrollment 35
Est. completion date December 31, 2021
Est. primary completion date July 30, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria: - Proven history of inflammatory bowel disease - Clinical evidence of mild, stable disease or remission - Mayo score = 4, Harvey Bradshaw index = 7 - Bothersome lower bowel symptoms of any of the following: frequency, urgency, incontinence, difficult evacuation, constipation Exclusion Criteria: - Significant medical or psychiatric comorbidity that in the opinion of the investigators would interfere with bowel function or adherence to the protocol - Clinically significant narcotic or substance abuse that in the opinion of the investigators would interfere with bowel function or adherence to the protocol - Recognised eating disorder - Non- English speaking or illiterate - Pregnancy - Previous pelvic floor physiotherapy - Current participant in another trial

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Behavioural treatment
2 to 6 sessions of behavioural training with a pelvic floor physiotherapist

Locations

Country Name City State
Australia St Vincent's Hospital Fitzroy Victoria

Sponsors (1)

Lead Sponsor Collaborator
St Vincent's Hospital Melbourne

Country where clinical trial is conducted

Australia, 

Outcome

Type Measure Description Time frame Safety issue
Other Change in Mayo Score Disease activity index for ulcerative colitis From baseline to study completion (up to 12 weeks) and at 1 year
Other Change in Harvey Bradshaw Index Disease activity index for Crohn's disease From baseline to study completion (up to 12 weeks) and at 1 year
Other Patient rating of satisfaction 7 point Likert scale rating satisfaction At study completion , up to 12 weeks
Other Change in pelvic floor muscle function Measurement of pelvic floor muscle movement using transperineal ultrasound From baseline to study completion (up to 12 weeks)
Primary Patient rating of improvement in symptoms Proportion of patients achieving a rating of 'moderately improved' or 'substantially improved' on a 7 point Likert scale ranging from 'substantially worse' to 'substantially improved' At study completion, up to 12 weeks
Secondary Change in Personal assessment of Constipation Symptoms (PAC-SYM) score 12 constipation symptoms each rated on a 5 point Likert scale (0=symptom absent to 4 = very severe. From baseline to study completion (up to 12 weeks) and at 1 year
Secondary Change in St Marks Faecal Incontinence Score Faecal incontinence symptom score ranging from 0-24 From baseline to study completion (up to 12 weeks) and at 1 year
Secondary Change in Inflammatory Bowel disease questionnaire (IBDQ) score Disease specific quality of life instrument with 32 questions covering 4 domains - bowel symptoms, systemic symptoms, emotional function, social function From baseline to study completion (up to 12 weeks) and at 1 year
Secondary Change in Short Form -36 (SF-36) score Generic quality of life score From baseline to study completion (up to 12 weeks) and at 1 year
Secondary Change in Hospital Anxiety and Depression Score (HADS) 14 item questionnaire indicating presence of anxiety or depression From baseline to study completion (up to 12 weeks) and at 1 year
Secondary Change in Brief Illness Perception Questionnaire score 9 item questionnaire designed to assess cognitive and emotional perception of illness From baseline to study completion (up to 12 weeks) and at 1 year
Secondary Change in Brief Cope score 28 item questionnaire assessing patients' strategies for coping with stress From baseline to study completion (up to 12 weeks) and at 1 year
Secondary Change in Inflammatory Bowel Disease Self-efficacy scale (IBD-SES) Disease specific scale with 29 items assessing how well patients believe they are managing their disease From baseline to study completion (up to 12 weeks) and at 1 year
Secondary Change in Euro-Qol (EQ-5D) Generic quality of life tool to calculate quality adjusted life years (QALYs) From baseline to study completion (up to 12 weeks) and at 1 year
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04046913 - The ADDapt Diet in Reducing Crohn's Disease Inflammation N/A
Active, not recruiting NCT04989907 - A Study in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) Receiving Vedolizumab in Real-World Practice in Switzerland
Recruiting NCT05316584 - A Novel Remote Patient and Medication Monitoring Solution to Improve Adherence and PerSiStence With IBD Therapy N/A
Active, not recruiting NCT04990258 - A 24-month Real Life PErsistence Efficacy and Safety Study in IBD Patients in REMission Switched From Intravenous Infliximab to Subcutaneous Infliximab CT-P13 Remsima®SC
Completed NCT06216223 - Laser Versus Surgery in Anal Diseases in Inflammatory Bowel Patients N/A
Enrolling by invitation NCT06015789 - Self-care in Patients Affected by Inflammatory Bowel Disease and Caregivers' Contribution to Self-care
Recruiting NCT06065995 - StoMakker Mobile Application N/A
Recruiting NCT03282786 - Comparison of Carbon Dioxide (CO2) to Air Insufflation in Colonoscopy in Patients With Inflammatory Bowel Disease N/A
Recruiting NCT06002074 - SMART Program Impact on Quality of Life in Inflammatory Bowel Diseases N/A
Recruiting NCT04960826 - Study of an Environmental Risk Factor in Crohn's Disease
Recruiting NCT05413941 - Internet-based Cognitive Behavioral Therapy in Inflammatory Bowel Disease N/A
Completed NCT03668249 - A Study to Characterize Multidimensional Model to Predict the Course of Crohn's Disease (CD)
Completed NCT00721812 - A First Time In Human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of GSK1399686 Phase 1
Recruiting NCT05809999 - IBD Neoplasia Surveillance RCT N/A
Recruiting NCT04138225 - The Ecological Role of Yeasts in the Human Gut
Recruiting NCT04991324 - Cholecalciferol Comedication in IBD - the 5C-study Phase 3
Completed NCT03173144 - Chronic Inflammatory Disease, Lifestyle and Treatment Response
Not yet recruiting NCT05043818 - A Clinical Study on the Screening of Intestinal Biomarkers in IBD Patients With Depression
Recruiting NCT03042091 - Neomycin and Metronidazole Hydrochloride With or Without Polyethylene Glycol in Reducing Infection in Patients Undergoing Elective Colorectal Surgery Early Phase 1
Not yet recruiting NCT02858557 - The Effect of Diet on Microbial Profile and Disease Outcomes in Patients With Inflammatory Bowel Diseases N/A